Gwo Xi Stem Cell Applied Technology is committed to developing cell therapies to satisfy unmet needs. Its manufacturing platform is fully compliant with medical regulations (Good Tissue Practice, GTP) in Taiwan. GwoXi has four clinical trials in process, namely GXHPC1 (liver cirrhosis), GXNPC1 (stroke), GXCPC1 (osteoarthritis) and GXIPC1 (diabetes).
